MeiraGTx Holdings (MGTX) Non-Current Deferred Tax Liability (2019 - 2023)
MeiraGTx Holdings' (MGTX) quarterly Non-Current Deferred Tax Liability came in at $184000.0 in Q3 2023, up 7.6% YoY from $171000.0 in Q3 2022, and down 2.65% on a QoQ basis from $189000.0 in Q2 2023.
MeiraGTx Holdings (MGTX) Non-Current Deferred Tax Liability (2019 - 2023) Analysis & Trends
MeiraGTx Holdings (MGTX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $184000.0 in Q3 2023.
- Quarterly Non-Current Deferred Tax Liability rose 7.6% year-over-year to $184000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $184000.0 (up 7.6% YoY) and the FY2022 annual result came in at $186000.0, down 5.1% from the prior year.
- Non-Current Deferred Tax Liability declined to $184000.0 in Q3 2023, from $189000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $214000.0 in Q4 2020 to a low of $171000.0 in Q3 2022.
- A 5-year average of $193676.5 and a median of $194159.0 in 2020 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability increased 9.71% — and 2022, when it fell 14.93%.
- Tracing MGTX's Non-Current Deferred Tax Liability over 5 years: stood at $195053.0 in 2019, then rose by 9.71% to $214000.0 in 2020, then fell by 8.41% to $196000.0 in 2021, then fell by 5.1% to $186000.0 in 2022, then dropped by 1.08% to $184000.0 in 2023.
- The last three Non-Current Deferred Tax Liability figures came in at $184000.0 (Q3 2023), $189000.0 (Q2 2023), and $189000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 184,000.00 |
| Sep 30, 2023 | 184,000.00 |
| Jun 30, 2023 | 189,000.00 |
| Jun 30, 2023 | 189,000.00 |
| Mar 31, 2023 | 189,000.00 |
| Mar 31, 2023 | 189,000.00 |
| Dec 31, 2022 | 186,000.00 |
| Dec 31, 2022 | 186,000.00 |
| Sep 30, 2022 | 171,000.00 |
| Sep 30, 2022 | 171,000.00 |
| Jun 30, 2022 | 181,000.00 |
| Jun 30, 2022 | 181,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Dec 31, 2021 | 196,000.00 |
| Dec 31, 2021 | 196,000.00 |
| Sep 30, 2021 | 201,000.00 |
| Sep 30, 2021 | 201,000.00 |
| Jun 30, 2021 | 206,000.00 |
| Jun 30, 2021 | 206,000.00 |